May Revised Urine Drug Screen Test Menu Effective mid-june Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory

Similar documents
Forensic Toxicology Scope of Testing and Detection Limits

June Beaker go-live updates. Billing and compliance. Chemistry. Drug screen testing. Referral Testing. Website

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

Drug Adherence Assessment Report

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY

Drugs Found in Medical Examiner Cases

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

Urine Drug Testing Methods 3-5

Laboratory Service Report

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

1. Amphetamine (Adderall, desoxyn, Dexedrine,dextrostat, spancap, oxydess II)

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)

2015 Annual Physician Notice

nextgen precision Test Report

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids

The Drug Testing Process. Employer or Practice

Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

Toxicology Practice and Procedure Handbook

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.

10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab

Urine Opioid Dependency Panel (UODP) 1

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Centre of Forensic Sciences

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Jonathan Rochon, Pier-Luc Plante, Serge Auger, Réal Paquin, Jacques Corbeil, Pierre Picard

ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)

PROFILE -V MEDTOXScan Drugs of Abuse Test System PACKAGE INSERT

Determination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS

ToxCup Drug Screen Cup Step-by Step Instructions

PROFILE -V MEDTOXScan Drugs of Abuse Test System INSERT

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

E XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

DRUGS OF ABUSE TEST CUPS 14-DRUG PANEL WITH ADULTERANTS Step by Step Instructions

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS

INTERPATH LABORATORY, INC. TEST UPDATES

Rapid Drug Test Cup Step-by Step Instructions

Dynacare Laboratories

Medications and Children Disorders

LC Application Note. Dangerous driver?

Retrospective Drug Use Review for the Use of Psychotropic Medications in Children

Therapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form

Prescriber s Guide. Stahl s Essential Psychopharmacology

Ultra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.

Supplementary Online Content

METHAMPHETAMINE & AMPHETAMINE

Appendix: Psychotropic Medication Reference Tables

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

SUPPLEMENTARY MATERIALS. Appendix 1. Definition of Suicidal Behavior Using ICD-9 Diagnostic Codes.

POINT OF CARE TESTING

Therapeutic Drugs Monitoring TDM 2016 Therapeutic Drugs Monitoring Scheme Application Form

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

Drug Adherence Assessment Report

Proof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples

Cross-reactivity reactivity in EMIT

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Medicines Formulary BNF Section 4 Central Nervous System

Drugs of Abuse I Serum

Urine drug testing it s not always crystal clear

Multi-Drug Screen Test

Oregon Health & Science University Department of Pathology, Division of Laboratory Medicine Core Laboratory

HEDIS Resource Guide Behavioral Health

C O P E. Milwaukee County Opioid-Related Overdose Report MILWAUKEE COMMUNITY OPIOID PREVENTION EFFORT

PROFILE -IV VISUAL PRODUCT INSERT

Analysis and Validation of Putative Substances Involved in Fatal Poisonings

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

Validation of an Automated Method to Remove

Quantitative Drug Testing Workgroup Notice (New, Revised and Deleted Codes for 2015)

One Step Multi-Drug Urine T-Cup

Pain Medication Management Program Monitors Patient Compliance

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Highly Sensitive Detection of Pharmaceuticals and Personal Care Products (PPCPs) in Water Using an Agilent 6495 Triple Quadrupole Mass Spectrometer

Ohana Community Care Services (CCS) Comprehensive Preferred Drug List (List of Covered Drugs)

Pain Medication Management Program Supports Patient Outcomes and Adherence

New Test Announcements

NorthSTAR. Pharmacy Manual

ZCPT S. Jog Rd. Suite Greenacres, FL Phone: (561)

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

Controlled Substance Monitoring in the Age of the Opioid Epidemic

South London and the Maudsley NHS Foundation Trust Medicines Formulary

Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers

ONLINE DAT II Results matter.

Transcription:

May 2014 Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory Revised Urine Drug Test Menu Effective mid-june 2014 To better address the complexities of drug screening for different patient groups, Allina Health Laboratory has revised the urine drug screen test menu, effective mid-june. This information does not include maternal/infant drug screening, which has separate requirements. The revised test menu consists of 4 drug screen panels: 1. Urine drugs of abuse presumptive screen, LAB597. A preliminary screen with limited clinical utility. 2. Limited Compliance Drug Monitor, LAB12507 - NEW - Optimized for monitoring patients in chemical dependency programs. 3. Comprehensive Compliance Drug Monitor, LAB8742. Comprehensive drug screen. Preferred test for monitoring patients in pain management programs. 4. Synthetic cannabinoids qualitative screen, LAB12396. Detects bath salts, K2, Spice. See following pages for comparison charts, lists of drugs detected, and sample reports. Important: Drug screening at Allina Health Laboratory cannot be used for any legal purpose, with the exception of certain maternal/infant specimens that are collected through special procedures.

Urine drugs of abuse presumptive screen, LAB597 - turnaround time stat (1 hour from arrival in lab) or routine (same day). Allina Health Laboratory receives many questions about the reliability and interpretation of this drug screen. This drug screen provides only a preliminary presumptive result and has limited clinical utility. Due to many cross reactions inherent in the rapid screen technology, this screen is not preferred for chemical dependency or pain management monitoring. When this test is ordered, consideration and professional judgment must be applied in evaluating a preliminary positive result. Confirmation testing should be ordered on any unexpected presumptive positive result; it is important to understand that many of these results will NOT confirm on further analysis by chromatography and mass spectrometry. For example, only 40-50% of screening positives for opiates or amphetamines will confirm. Important points to remember about this drug screen (and all rapid presumptive drug screens and cup tests): 1. This screen cannot distinguish between abused drugs and many common prescribed and over-the-counter medications. 2. Certain foods or legitimate medications may interfere with screening tests and cause false positive results. 3. It is not possible to predict all interferences and false positive reactions because of individual differences in medications, drug metabolism, and diet. 4. The number of screening positives that confirm on further testing is as low as 40%, depending on the drug and patient population. Do not assume that a presumptive positive result is real. Order confirmation testing if the result is unexpected. Limited Compliance Drug, LAB 12507, *NEW* - turnaround time 3-5 days. This screen is the preferred test for monitoring patients in chemical dependency programs. The screen includes alcohol metabolites and important drugs of abuse. Confirmations are automatically performed for positives except for THC (a separate order would be required if confirmation is needed.) Comprehensive Compliance Drug Monitor, LAB8742 - turnaround time 5-7 days. This screen is comprehensive and preferred for monitoring patients in pain management programs and other medical indications for nonemergency comprehensive screening. Results are definitive and confirmed. The screen includes over 170 drugs in 22 classes. Quantitative results (normalized to creatinine) are reported for many drugs. Synthetic Cannabinoid (K2, Spice, bath salts) Qualitative,Lab12396 - turnaround time 5-7 days. Synthetic cannabinoids such as K2, Spice, and bath salts require special technology for detection and are not included in the other screening panels. 2

ALLINA HEALTH LABORATORY - REVISED URINE DRUG SCREENING TEST MENU EFFECTIVE June 13, 2014 In House Rapid Presump ve LAB597 presump ve screen only Limited Compliance *NEW* LAB12507 for monitoring chemical dependency pa ents Comprehensive Drug & Compliance Monitor LAB8742 (aka ToxAssure or MedWatch) Pain compliance and nonemergency comprehensive drug screening Synthe c Cannabinoid Qualita ve LAB12396 K2, Spice, "bath salts" TAT Performing laboratory Descrip on Automa c confirma ons ROUTINE (same day) or STAT (1 hour from receipt in laboratory) ROUTINE only. Cannot order stat. 3 5 days. ROUTINE only. Cannot order stat. 5 7 days ROUTINE only. Cannot order stat. 3 5 days. Allina Health Laboratory MedTox MedTox MedTox Clinical u lity is limited. Should be ordered only by providers who understand the limita ons of an body based drug screens. Posi ve results must be interpreted with cau on. ing results are preliminary only; many screening posi ves will NOT confirm on further tes ng. Confirma on tes ng should be ordered for any unexpected posi ve (or nega ve)results. NONE. Confirma ons are NOT automa cally performed and must be ordered separately. 5 7 day turnaround me for confirma ons. Rou ne screening of pa ents in the chemical dependency program. Included and automa cally performed, except THC. (Confirma on for THC must be specifically ordered if needed.) Rou ne comprehensive drug screening for compliance monitoring in Detec on of synthe c pain management or other cannabinoids medical indica ons where comprehensive screening is needed. Unnecessary, results are comprehensive and defini ve. Results are confirmed. Repor ng Qualita ve results (presump ve posi ve/not detected) Qualita ve results (posi ve/nega ve). Qualita ve (pos/neg) and Quan ta ve (value normalized to crea nine for many drugs) Qualita ve. (For quan ta ve results, order LAB12521) 3

DRUG COMPARISON CHART: GENERAL DRUG SCREEN PANELS AVAILABLE FROM ALLINA HEALTH LABORATORY Effective June 13, 2014 Drugs of Abuse LAB597 NEW Limited Compliance LAB12507 DETECTION THRESHHOLD (ng/ml) Comprehensive Compliance Drug (ToxAssure) LAB8742 DRUG CLASS DRUGS REPORTED Ethyl Glucuronide Not included 250 *Opiates: codeine, hydrocodone, hydromorphone, morphine, dihydrocodeine Etheyl Sulfate Not included 100 *Oxycodones: oxycodone, oxymorphone Amphetamines 500 500 *Buprenorphine: buprenorphine, norbuprenorphine Methamphetamine 500 No separate test, metabolizes to amphetamine *Methadone: methadone, EDDP Barbiturates 200 200 *Amphetamines: methamphetamine, amphetamine, methylenedioxymethamphetamine (MDMA), methylenedioxyamphetamine (MDA), methylenedioxyethylamphetamine (MDEA) Benzodiazepines 150 200 *Cocaine MTB: cocaine, benzoylecgonine, cocaethylene Cocaine Metabolite 50 150 *Benzodiazepines: alprazolam, alpha-hydroxyalprazolam, chlordiazepoxide (as metabolites), clonazepam, 7-aminoclonazepam, clorazepate (as metabolite), desalkylflurazepam, diazepam, desmethyldiazepam, lorazepam, midazolam, oxazepam, temazepam, alpha-hydroxytriazolam Fentanyl Not included 1 Other Hallucinogens: ketamine, phencyclidine "Opiates" includes: 100 300 *Cannabinoids/ 9 -carboxy-tetrahydrocannabinol THC: (carboxy-thc) amitriptyline, amoxapine, 8- hydroxyamoxapine,bupropion, citalopram, desmethylcitalopram, escitalopram, clomipramine, desmethylclomipramine, desipramine, desvenlafaxine, Codeine 50 300 Antidepressants: doxepin, desmethyldoxepin, duloxetine, fluoxetine, norfluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nortriptyline, protriptyline, sertraline, desmethylsertraline, trazodone, trimipramine, venlafaxine, desmethylvenlafaxine Morphine 100 300 Barbiturates: amobarbital, barbital, butabarbital, butalbital, mephobarbital, pentobarbital, phenobarbital, secobarbital, thiopental Heroin 100 300 *Ethyl Alcohol: ethyl alcohol 4

DRUG Drugs of Abuse LAB597 Limited Compliance LAB12507 DETECTION THRESHHOLD (ng/ml) Comprehensive Compliance Drug (ToxAssure) LAB8742 DRUG CLASS Hydrocodone 400 300 Sympathomimetics: DRUGS REPORTED ephedrine, methcathinone, methylphenidate, phenmetrazine, phentermine, phenylpropanolamine, pseudoephedrine Hydromorphone 800 300 *Fentanyl and Analogs: fentanyl, norfentanyl, sufentanil, alfentanil Dihydrocodeine 100 300 *Other Opiodes: butorphanol, levorphanol, meperidine, normeperidine, nalbuphine, naltrexone, pentazocine, propoxyphene, norpropoxyphene, tapentadol, tramadol, O- desmethyltramadol, N- desmethyltramadol, 6MAM (Heroin-Specific) Not Included 10 Anticonvulsants: carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine MHD, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, zonisamide Oxycodone 100 100 Muscle Relaxants: PCP (Phencyclidine) 25 Not included Other Sedative/ Hypnotics: THC Metabolite 50 50 Antidepressants: Methadone 200 300 Antipsychotics: baclofen, carisoprodol, cyclobenzaprine, meprobamate, metaxolone, methocarbamol, orphenadrine, tizanidine eszopiclone, zaleplon, zopiclone, zolpidem amitriptyline, amoxapine, 8- hydroxyamoxapine,bupropion, citalopram, desmethylcitalopram, escitalopram, clomipramine, desmethylclomipramine, desipramine, desvenlafaxine, doxepin, desmethyldoxepin, duloxetine, fluoxetine, norfluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nortriptyline, protriptyline, sertraline, desmethylsertraline, trazodone, trimipramine, venlafaxine, desmethylvenlafaxine aripiprazole, chlorpromazine, clozapine, norclozapine, fluphenazine, haloperidol, loxapine, 8- hydroxyloxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, prochlorperazine, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, ziprasidone 5

DRUG Drugs of Abuse LAB597 Limited Compliance LAB12507 DETECTION THRESHHOLD (ng/ml) Comprehensive Compliance Drug (ToxAssure) LAB8742 DRUG CLASS Propoxyphene Not included 300 Analgesics/NSAIDS Buprenophine 10 5 Antihistamines: Tramadol Not included 200 Local Anesthetics: Miscellaneous: DRUGS REPORTED acetaminophen, ibuprofen, ketoprofen, naproxen, oxaprozin, salicylate brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, hydroxyzine, promethazine, pyrilamine, triprolidine bupivacaine, lidocaine, mepivacaine, procaine atenolol, benztropine, caffeine (large amounts), clonidine, dextromethorphan, dextrorphan, diltiazem, guaifenesin, metoprolol, propranolol, theophylline, verapamil 6

7

8

9

10

11

12

13

For questions, comments, or suggestions about this newsletter or other laboratory issues, please contact Lauren Anthony, MD, Medical Director of Allina Health Laboratory, (612) 863-0409 or Lauren.Anthony@allina.com 14